← Oncology Approval Tracker

FDA DECISION ·

Cyclophosphamide injection (first generic)

cyclophosphamide · Nexus Pharmaceuticals

First generic approvalFirst genericMultiple solid tumors and blood cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

The first generic of the referenced 200 mg/mL cyclophosphamide solution for labeled malignant diseases, including select lymphomas, leukemias, myeloma, neuroblastoma, ovarian and breast cancers, and retinoblastoma.

LAMPGEN ANALYSIS

Why it matters

The action expands access to a specific ready-to-dilute presentation of an established antineoplastic.

What research teams should watch

Check the reference presentation, concentration and vial handling; products that require reconstitution use different instructions.

PRIMARY RECORDS

Sources